regeneron pharmaceuticals semaglutide announced on January 30, 2026, that its experimental obesity drug candidate delivers significant cholesterol-lowering benefits on top of weight loss—a differentiation strategy aimed at competing with Eli Lilly's and GDF8 and activin A blockade

Cardiovascular disease Drugs like Ozempic and Wegovy can help reduce the risk of heart attacks , strokes, and other cardiovascular events and improve symptoms of heart failure

"Cardi B goes both soft and hard in her new single, "Be Careful""

Evidence from TRIUMPH-4 and TRIUMPH-1: Mostly rated as "mild" by participants Rarely led to discontinuation (12%) No progression to serious neurological issues Reversible when medication stopped (in Phase 2 extension) When to Call Your Doctor About Dysesthesia Call if you experience: Severe pain (not just tingling) Progressive worsening despite dose stability Loss of coordination or balance Weakness in hands or feet Symptoms interfering with daily life Likely benign if: Mild tingling only Stable or improving over time No pain or weakness Managing Nausea: The Most Common Side Effect Why GLP-1 Medications Cause Nausea GLP-1 slows gastric emptying food stays in stomach longer Longer gastric residence feeling of fullness (desired!) or nausea (not desired) Brain signaling changes nausea sensation Good news: This is the SAME mechanism producing weight loss

Many clinics turned to compounded versions of semaglutide during the shortage to maintain patient care